ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.80
-0.48 (-3.65%)
As of 10:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.28
Open13.20
Bid12.95 x 1800
Ask12.97 x 1000
Day's Range12.77 - 13.32
52 Week Range10.21 - 23.62
Volume96,765
Avg. Volume384,106
Market Cap705.447M
Beta (3Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire5 days ago

    Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at JMP Securities Life Sciences Conferences Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire11 days ago

    Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the  U.S. Food and Drug Administration (FDA) has announced a Psychopharmacologic Drugs Advisory Committee meeting to be held on July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone with the proposed indication of treatment of schizophrenia in adults. Lumateperone is a novel investigational drug with an NDA currently under review by FDA as a treatment of schizophrenia in adults.

  • GlobeNewswire25 days ago

    Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at Jefferies 2019 Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswirelast month

    Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2019 RBC Capital Markets Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the presentation of posters highlighting the lumateperone program in schizophrenia at the 2019 American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18-22, 2019. Lumateperone is a novel investigational drug currently under review by the FDA as a potential treatment for adults with schizophrenia.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    NEW YORK, May 08, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, May 8, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2019. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research revolutionized our understanding of the biochemistry of the brain. Dr. Greengard’s Nobel prize-winning work in intracellular signaling was the foundation of the company’s formation in 2002. “We are deeply saddened by the news of Paul’s passing.

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone, an investigational drug, in patients with stable symptoms of schizophrenia. Results were also presented on the improvements in symptoms of depression in patients with moderate to severe co-morbid depression.  The data were presented at the 2019 Congress of the Schizophrenia International Research Society (SIRS), which was held in Orlando, Florida, April 10-14, 2019. “Schizophrenia is a multidimensional illness with high rates of comorbidities, including depressive symptoms.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market Access, Policy and Government Affairs.  Mr. Bardi has over 30 years of biopharmaceutical and health system industry experience with a strong track record of innovation and building high-performing Market Access, Government Affairs, and Digital Medicine business development teams and capabilities across many disease areas.

  • GlobeNewswire4 months ago

    Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 39th Annual Healthcare Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire4 months ago

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    NEW YORK, Feb. 27, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswire4 months ago

    Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire4 months ago

    Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, February 27, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire4 months ago

    Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE6 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, NY / ACCESSWIRE / January 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.

  • GlobeNewswire6 months ago

    Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire6 months ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)

    NEW YORK, Dec. 18, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies,.

  • GlobeNewswire6 months ago

    Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease

    “We are disappointed for patients suffering from Alzheimer's disease that the interim analysis did not detect a signal that would warrant continuation of this study. Effective clinical study design is a challenge, especially for a therapeutic indication for which there are no approved treatments," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • GlobeNewswire6 months ago

    Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced favorable results from  the second part  of its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone in patients with stable symptoms of schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held in Hollywood, FL, December 9-13, 2018. Poster T184 entitled "Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia" is being presented today from 5:30 pm — 7:30 pm during Poster Session II. The poster presented data demonstrating that lumateperone, administered for up to one year, was generally well tolerated and exhibited statistically significant improvements from baseline on key safety measures of body weight, cardiometabolic and endocrine parameters, without motor side effects often associated with other antipsychotic medications.

  • GlobeNewswire6 months ago

    Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2019. “The FDA’s acceptance of our NDA submission for lumateperone for the treatment of schizophrenia represents an important milestone and brings us closer to offering a potential advance in the treatment of patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • GlobeNewswire8 months ago

    Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2018. This portion of the study follows patients for up to 1-year of treatment with lumateperone after a switch from standard-of-care antipsychotic therapy.